Congress Weighs Value Of Pediatric Exclusivity
A provision of the U.S. Senate drug user fee bill, S.1082, would lower pediatric exclusivity from six months to three months if the drug is considered a blockbuster, or one that made over $1 billion in annual sales.
The bill has already passed in the Senate. The U.S. House of Representatives is considering how to approach...
To view the full article, register now.